While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Rifaximin-alpha use decreases healthcare utilisation in patients with cirrhosis and hepatic encephalopathy, with fewer hospital visits and encephalopathy episodes in 6 months after prescription.

ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis, the bookrunner on the deal ...

Bajaj JS, et al. Rifaximin monotherapy is more effective than lactulose monotherapy for reducing the risk of overt hepatic encephalopathy (OHE) recurrence and all-cause mortality: An analysis of ...

Although rifaximin was well-tolerated in patients with severe cirrhosis and ascites, it did not improve transplant-free survival and cirrhosis-related complications and “cannot be recommended ...

Novartis AG raised its profit forecast for a third time as investors look beyond this year for clues to the Swiss drugmaker’s future after the spinoff of its Sandoz generics business.

Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority. Click here to see why NVS stock is a Hold.

Novartis' generic and biosimilar business, Sandoz, began trading as a standalone company, falling short of market expectations.

Sandoz shares dipped on their market debut on Wednesday after the generic and biosimilar drugmaker was valued at a lower-than-expected 10.3 billion Swiss francs ($11.2 billion) in its spin-off ...

Novartis AG NVS confirmed its plans for a 100% spin-off of the Sandoz business on October 4 after shareholders approved it earlier this month. Novartis also said key regulatory approvals have been ...